Latest GILD reports update at 2024-02-23: 2023 ∙ 2022 ∙ 2021
  1. Home
  2. Stock quotes
  3. Stock Gilead Sciences
Gilead Sciences logo

Gilead Sciences GILD

$ 65.42 0.23%
mail-toReport an Error

Country

 usaUSA

IPO year

 1992

Industry

 Biotechnology

Stock Exchange

 NASDAQ GLOBALSPB

CEO

 Mr. Daniel O'Day

Employees in the company

 11 800

Shares

 1.25 B

Market Cap[1]

 $ 81.6 B

EBITDA (LTM)

 $ 10.6 B

P/E (LTM)

 16.66

P/S (LTM)

 3.73

EPS (LTM)

 4.83

Gilead Sciences is an American biopharmaceutical company that specializes in the development and production of innovative drugs for the treatment of various diseases.

The company was founded in 1987 and is currently one of the leaders in the field of biotechnology. It conducts research and development in areas such as infectious diseases, oncology, hepatitis, HIV infection, and other areas of medicine.

The company's most well-known and successful product is Sovaldi, which is the first drug to effectively treat chronic hepatitis C. The company also produces drugs for the treatment of blood cancer and HIV infection.

Gilead Sciences actively collaborates with scientific and medical institutions around the world and invests in the development of new methods for treating diseases. The company also provides training programs for medical professionals and patients.

Gilead Sciences continues to grow and expand its activities to help people around the world fight various diseases.

Other stocks of industry "Biotechnology"

Issuer Price % 24h Market Cap Exchange Country
Pluristem Therapeutics Pluristem Therapeutics
PSTI
 		$ 1.03 -1.9 % $ 33.3 M Nasdaq Global Select Market israelIsrael
Cortexyme Cortexyme
CRTX
 		$ 1.88 -1.05 % $ 67.1 M Nasdaq Global Select Market,SPB usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
 		$ 0.27 -29.58 % $ 126 M Nasdaq Global Select Market usaUSA
Cerus Corporation Cerus Corporation
CERS
 		$ 1.71 0.59 % $ 308 M Nasdaq Global Market usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
 		$ 0.43 -16.75 % $ 25.8 M Nasdaq Capital Market usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
 		$ 1.47 -5.16 % $ 5.39 M Nasdaq Capital Market usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
 		$ 4.93 1.02 % $ 90.8 M Nasdaq Global Select Market britainBritain
Cue Biopharma Cue Biopharma
CUE
 		$ 1.37 -3.19 % $ 62.7 M Nasdaq Capital Market,SPB usaUSA
Advaxis Advaxis
ADXS
 		$ 0.31 -9.65 % $ 45.9 M Nasdaq Capital Market usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
 		$ 11.21 0.36 % $ 1.44 B Nasdaq Capital Market usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
 		$ 3.93 -5.76 % $ 99.8 M Nasdaq Capital Market usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
 		$ 6.2 - $ 154 M Nasdaq Capital Market usaUSA
Zymeworks Zymeworks
ZYME
 		$ 6.42 - $ 404 M NYSE canadaCanada
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
 		$ 9.21 0.55 % $ 245 M Nasdaq Capital Market usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
 		$ 10.5 - $ 231 M Nasdaq Global Market usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
 		$ 1.44 -1.71 % $ 68.3 M NYSE American,SPB usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
 		$ 9.5 - $ 1.7 B Nasdaq Global Select Market usaUSA
AIkido Pharma AIkido Pharma
AIKI
 		$ 3.17 1.93 % $ 17.4 M Nasdaq Capital Market usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
 		$ 2.58 -4.8 % $ 255 M Nasdaq Global Select Market usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
 		$ 0.56 7.23 % $ 2.72 M Nasdaq Global Select Market usaUSA

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.